Omeprazole Blocks Eotaxin-3 Expression by Oesophageal Squamous Cells from Patients with Eosinophilic Oesophagitis and GORD

Overview

Journal Gut

Specialty Gastroenterology

Date 2012 May 15

PMID 22580413

Citations 147

Authors

Edaire Cheng

Xi Zhang

Xiaofang Huo

Chunhua Yu

Qiuyang Zhang

David H Wang

Stuart Jon Spechler

Rhonda F Souza

Affiliations

Soon will be listed here.

Abstract

Objective: Eosinophilic oesophagitis (EoE) and gastro-oesophageal reflux disease (GORD) can have similar clinical and histological features. Proton pump inhibitors (PPIs) are used to distinguish the disorders, with the assumption that only GORD can respond to PPIs. Oesophageal expression of eotaxin-3 stimulated by Th2 cytokines might contribute to oesophageal eosinophilia in EoE. Th2 cytokine effects on the oesophagus in GORD are not known. The objective of the authors was to explore the molecular mechanisms of Th2 cytokines on eotaxin-3 expression by oesophageal squamous cells from patients with GORD and EoE, and the effects of omeprazole on that eotaxin-3 expression.

Design: Using telomerase-immortalised and primary cultures of oesophageal squamous cells from GORD and EoE patients, the authors measured eotaxin-3 protein secretion stimulated by Th2 cytokines (interleukin (IL)-4 and IL-13). Eotaxin-3 promoter constructs were used to study transcriptional regulation. Cytokine-induced eotaxin-3 mRNA and protein expression were measured in the presence or absence of omeprazole.

Results: There were no significant differences between EoE and GORD primary cells in cytokine-stimulated eotaxin-3 protein secretion levels. In EoE and GORD cell lines, IL-4 and IL-13 activated the eotaxin-3 promoter, and significantly increased eotaxin-3 mRNA and protein expression. Omeprazole blocked the cytokine-stimulated increase in eotaxin-3 mRNA and protein expression in EoE and GORD cell lines.

Conclusion: Oesophageal squamous cells from GORD and EoE patients express similar levels of eotaxin-3 when stimulated by Th2 cytokines, and omeprazole blocks that eotaxin-3 expression. These findings suggest that PPIs might have eosinophil-reducing effects independent of effects on acid reflux and that response to PPIs might not distinguish EoE from GORD.

Citing Articles

Exploring the Impact of Gender on the Characteristics and Complications of Eosinophilic Esophagitis.

Patel H, Elmer J, Liaquat H JGH Open. 2024; 8(12):e70059.

PMID: 39713748 PMC: 11660561. DOI: 10.1002/jgh3.70059.

Eosinophilic esophagitis.

Erdle S, Carr S, Chan E, Robertson K, Watson W Allergy Asthma Clin Immunol. 2024; 20(Suppl 3):72.

PMID: 39702284 PMC: 11660462. DOI: 10.1186/s13223-024-00929-0.

The Role of Esophageal Physiologic Tests in Eosinophilic Esophagitis.

Wakim El-Khoury J, Safroneeva E, Schoepfer A Inflamm Intest Dis. 2024; 9(1):296-303.

PMID: 39659395 PMC: 11631170. DOI: 10.1159/000542435.

Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.

Schoepfer A, Safroneeva E Inflamm Intest Dis. 2024; 9(1):199-209.

PMID: 39474328 PMC: 11521425. DOI: 10.1159/000540275.

From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis.

Barchi A, Mandarino F, Yacoub M, Albarello L, Massimino L, Savarino E Biomolecules. 2024; 14(9).

PMID: 39334846 PMC: 11429508. DOI: 10.3390/biom14091080.

References

Cortes J, Rivas M, Molina-Infante J, Gonzalez-Nunez M, Perez-G M, Masa J . Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol. 2009; 124(3):607-10, 610.e1. DOI: 10.1016/j.jaci.2009.06.023. View

Spechler S, Genta R, Souza R . Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007; 102(6):1301-6. DOI: 10.1111/j.1572-0241.2007.01179.x. View

Tobey N, Hosseini S, Argote C, Dobrucali A, Awayda M, Orlando R . Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol. 2003; 99(1):13-22. DOI: 10.1046/j.1572-0241.2003.04018.x. View

Bhattacharya B, Carlsten J, Sabo E, Kethu S, Meitner P, Tavares R . Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease. Hum Pathol. 2007; 38(12):1744-53. DOI: 10.1016/j.humpath.2007.05.008. View

Liacouras C, Furuta G, Hirano I, Atkins D, Attwood S, Bonis P . Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011; 128(1):3-20.e6. DOI: 10.1016/j.jaci.2011.02.040. View

Blanchard C, Mingler M, Vicario M, Abonia J, Wu Y, Lu T . IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol. 2007; 120(6):1292-300. DOI: 10.1016/j.jaci.2007.10.024. View

Jaiswal K, Morales C, Feagins L, Gandia K, Zhang X, Zhang H . Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). Dis Esophagus. 2007; 20(3):256-64. DOI: 10.1111/j.1442-2050.2007.00683.x. View

Kobayashi I, Yamamoto S, Nishi N, Tsuji K, Imayoshi M, Inada S . Regulatory mechanisms of Th2 cytokine-induced eotaxin-3 production in bronchial epithelial cells: possible role of interleukin 4 receptor and nuclear factor-kappaB. Ann Allergy Asthma Immunol. 2004; 93(4):390-7. DOI: 10.1016/S1081-1206(10)61399-3. View

Cheng L, Cao W, Behar J, Fiocchi C, Biancani P, Harnett K . Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther. 2006; 319(1):117-26. DOI: 10.1124/jpet.106.106104. View

10.

Blanchard C, Wang N, Stringer K, Mishra A, Fulkerson P, Abonia J . Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006; 116(2):536-47. PMC: 1359059. DOI: 10.1172/JCI26679. View

11.

Newbold R, Overell R, Connell J . Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens. Nature. 1982; 299(5884):633-5. DOI: 10.1038/299633a0. View

12.

Untersmayr E, Jensen-Jarolim E . The effect of gastric digestion on food allergy. Curr Opin Allergy Clin Immunol. 2006; 6(3):214-9. DOI: 10.1097/01.all.0000225163.06016.93. View

13.

Morales C, Gandia K, Ramirez R, Wright W, Shay J, Spechler S . Characterisation of telomerase immortalised normal human oesophageal squamous cells. Gut. 2003; 52(3):327-33. PMC: 1773571. DOI: 10.1136/gut.52.3.327. View

14.

Molina-Infante J, Ferrando-Lamana L, Ripoll C, Hernandez-Alonso M, Mateos J, Fernandez-Bermejo M . Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 2010; 9(2):110-7. DOI: 10.1016/j.cgh.2010.09.019. View

15.

Ngo P, Furuta G, Antonioli D, Fox V . Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006; 101(7):1666-70. DOI: 10.1111/j.1572-0241.2006.00562.x. View

16.

Zhang H, Zhang X, Chen X, Thomas D, Hormi-Carver K, Elder F . Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol. 2008; 295(3):G470-8. PMC: 2536777. DOI: 10.1152/ajpgi.90262.2008. View

17.

Winter H, Madara J, Stafford R, Grand R, Quinlan J, Goldman H . Intraepithelial eosinophils: a new diagnostic criterion for reflux esophagitis. Gastroenterology. 1982; 83(4):818-23. View

18.

Hebenstreit D, Luft P, Schmiedlechner A, Duschl A, Horejs-Hoeck J . SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol. 2004; 42(3):295-303. DOI: 10.1016/j.molimm.2004.09.004. View

19.

Hahn W, Counter C, Lundberg A, Beijersbergen R, Brooks M, Weinberg R . Creation of human tumour cells with defined genetic elements. Nature. 1999; 400(6743):464-8. DOI: 10.1038/22780. View

20.

Hoeck J, Woisetschlager M . Activation of eotaxin-3/CCLl26 gene expression in human dermal fibroblasts is mediated by STAT6. J Immunol. 2001; 167(6):3216-22. DOI: 10.4049/jimmunol.167.6.3216. View